A new study conducted at Sichuan Agricultural University shows that the COX-2 selective NSAID drug celecoxib (Celebrex) extends lifespan in drosophila.
The researchers report that "2,5-dimethyl-celecoxib, a derivative of the anti-inflammatory drug celecoxib, can extend Drosophila life span and delay aging by a mechanism involving insulin signaling and target of rapamycin signaling. Importantly, its positive effects were apparent when the treatment window was restricted to the beginning of life of the later half. 2,5-Dimethyl-celecoxib-induced longevity was associated with improvements in physical activity, intestinal integrity, and increased autophagy. In addition, 2,5-dimethyl-celecoxib exhibited protective effects against several kinds of stress such as starvation and heat."
The question is -- do the positive effects of celecoxib outweigh the negative effects (a 37% increased risk of major vascular events such as heart attack and stroke)?